Alnylam Pharmaceuticals, Inc. Announce Health Canada’s Approval of Onpattro™ (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. To learn more, please visit: http://investors.alnylam.com/news-releases/news-release-details/alnylam-launches-onpattror-patisiran-treatment-polyneuropathy
1 (905) 580-2802
info@madhattr.ca
